<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>PURPOSE: CD52 is a GPI-linked <z:chebi fb="2" ids="17089">glycoprotein</z:chebi> expressed by B cells, T cells, monocytes, and macrophages </plain></SENT>
<SENT sid="1" pm="."><plain>The humanized monoclonal antibody alemtuzumab (CAMPATH-1H) is specific for CD52 and is Food and Drug Administration - approved for the treatment of relapsed or refractory <z:hpo ids='HP_0005550'>chronic lymphocytic leukemia</z:hpo> (CLL) </plain></SENT>
<SENT sid="2" pm="."><plain>The utility of CAMPATH in the treatment of other hematologic <z:hpo ids='HP_0002664'>neoplasms</z:hpo> has been explored; however, a comprehensive survey of CD52 expression among a broad spectrum of WHO-defined <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> types has not been completed </plain></SENT>
<SENT sid="3" pm="."><plain>EXPERIMENTAL DESIGN: We evaluated 294 hematologic <z:hpo ids='HP_0002664'>neoplasms</z:hpo> for the presence of CD52 using standard immunohistochemical techniques on paraffin-embedded biopsy specimens fixed with formalin, B-Plus, Zenker's <z:chebi fb="22" ids="15366">acetic acid</z:chebi>, or B5-formalin </plain></SENT>
<SENT sid="4" pm="."><plain>RESULTS: The vast majority of low-grade B cell <z:hpo ids='HP_0005523'>lymphoproliferative disorders</z:hpo> (CLL/small lymphocytic <z:hpo ids='HP_0001909'>leukemia</z:hpo>, follicular <z:hpo ids='HP_0002665'>lymphoma</z:hpo>, lymphoplasmacytic <z:hpo ids='HP_0002665'>lymphoma</z:hpo>, hairy cell <z:hpo ids='HP_0001909'>leukemia</z:hpo>, and mucosa-associated lymphoid tissue <z:hpo ids='HP_0002665'>lymphomas</z:hpo>) express CD52 </plain></SENT>
<SENT sid="5" pm="."><plain>In addition, we found that the majority of precursor B cell <z:hpo ids='HP_0006721'>acute lymphoblastic leukemia</z:hpo>/<z:hpo ids='HP_0002665'>lymphomas</z:hpo> express this antigen </plain></SENT>
<SENT sid="6" pm="."><plain>In contrast, there is surprising <z:hpo ids='HP_0001425'>heterogeneity</z:hpo> in CD52 expression among more aggressive B cell <z:hpo ids='HP_0002665'>lymphomas</z:hpo>, with 25% of cases of diffuse large B cell <z:hpo ids='HP_0002665'>lymphoma</z:hpo> and Burkitt <z:hpo ids='HP_0002665'>lymphoma</z:hpo> demonstrating no detectable CD52 </plain></SENT>
<SENT sid="7" pm="."><plain>In addition, the majority of <z:hpo ids='HP_0002664'>neoplasms</z:hpo> of the T cell lineage are negative for the antigen, including most cases of precursor T cell <z:hpo ids='HP_0006721'>acute lymphoblastic leukemia</z:hpo>/<z:hpo ids='HP_0002665'>lymphoma</z:hpo>, anaplastic large cell <z:hpo ids='HP_0002665'>lymphoma</z:hpo>, and peripheral T cell <z:hpo ids='HP_0002665'>lymphoma</z:hpo>, not otherwise specified </plain></SENT>
<SENT sid="8" pm="."><plain>Finally, the vast majority of cases of <z:hpo ids='HP_0004808'>acute myeloid leukemia</z:hpo>, Hodgkin <z:hpo ids='HP_0002665'>lymphoma</z:hpo>, and <z:hpo ids='HP_0006775'>multiple myeloma</z:hpo> are negative for CD52 expression </plain></SENT>
<SENT sid="9" pm="."><plain>CONCLUSION: In contrast with CLL, the variable expression of CD52 among other <z:e sem="disease" ids="C0376545" disease_type="Neoplastic Process" abbrv="">hematologic malignancies</z:e> suggests that target validation on a case-by-case basis will likely be necessary to guide the rational analysis of CAMPATH therapy </plain></SENT>
</text></document>